Status:

COMPLETED

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Advanced Solid Tumor

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

Eligibility Criteria

Inclusion

  • Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1
  • Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor
  • Eastern cooperative oncology group performance status of 0 or 1
  • Women of childbearing potential must agree to follow methods of contraception

Exclusion

  • Participants with active, known or suspected autoimmune disease
  • Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
  • Uncontrolled or significant cardiovascular disease
  • History of or with active interstitial lung disease or pulmonary fibrosis
  • Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study
  • History of allergy or hypersensitivity to study drug components
  • Other protocol-defined inclusion/exclusion criteria apply

Key Trial Info

Start Date :

July 14 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 22 2024

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT04349267

Start Date

July 14 2020

End Date

August 22 2024

Last Update

December 17 2025

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Local Institution - 0028

Sioux Falls, South Dakota, United States, 57104

2

Local Institution - 0001

Germantown, Tennessee, United States, 38138

3

Local Institution - 0014

Edmonton, Alberta, Canada, T6X 1E8

4

Local Institution - 0011

Vancouver, British Columbia, Canada, V5Z 4E6